POM Company Profile and Key Details

POMDOCTOR Ltd generated EPS of $nan over the past year. Five-year average earnings growth is -13.4%.

Short-term trend indicators are bullishly aligned (SMA20 0.8%, SMA50 -16.08%, SMA200 -89.82%). The stock’s 14-day RSI is 33.53 (weak momentum), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.35% below its high and over 21.76% above its low. Average 10-day trading volume of 4.45 million shares is significantly above the 3-month average of 1.51 million, indicating heightened recent market interest.

POMDOCTOR Ltd (NASDAQ:POM) closed at $0.07 USD, losing -$0.46 (-85.88%) from the previous close of $0.53. The stock is currently mid-range between its 52-week high and low $0.06 and $6.43. With a market capitalization of about $8.02 million, POMDOCTOR Ltd is classified as a micro-cap and shows higher-than-market volatility (beta ~3.90). Key stats such as the average daily volume over the past year has been around 1.55 million shares, trading with heavier-than-usual volume. Headquartered in Guangzhou, None, POMDOCTOR Ltd operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Zhenyang Shi, the company employs approximately 156 people and listed since October 08, 2025. Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products.

POMDOCTOR Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.23. This means the shares are trading below this model’s fair value.

POMDOCTOR Ltd (NASDAQ:POM) shares are flat 0.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows POMDOCTOR Ltd trading at a premium to the broader market with a P/E of -0.95. Our AI forecast model points to short-term strength (273.33% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that POMDOCTOR Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 273.33%, with price expected at $0.28 by May 22, 2026, within a range of $0.18 to $0.38 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by August 06, 2026, with a range of $0.00 to $0.10. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 07, 2027, within a range of $0.00 to $0.16.

POMDOCTOR Ltd trades at a P/E ratio of -0.95, slightly below the S&P 500 average, with a price-to-sales ratio of 0.36 and a price-to-book ratio of -0.06 indicating negative book value, which may reflect financial stress. The P/FCF stands at -7.64, also below market averages.